MA41999A - Compositions d'acide obéticholique et procédés d'utilisation - Google Patents

Compositions d'acide obéticholique et procédés d'utilisation

Info

Publication number
MA41999A
MA41999A MA041999A MA41999A MA41999A MA 41999 A MA41999 A MA 41999A MA 041999 A MA041999 A MA 041999A MA 41999 A MA41999 A MA 41999A MA 41999 A MA41999 A MA 41999A
Authority
MA
Morocco
Prior art keywords
methods
acid compositions
obeticholic acid
obeticholic
compositions
Prior art date
Application number
MA041999A
Other languages
English (en)
Inventor
Jeffrey Edwards
Lise Eliot
Roya Hooshmand-Rad
Masashi Kagihiro
Richard G Lancaster
Leigh A Macconell
Tonya K Marmon
Mitsuhiro Matono
Kay K Olmstead
Richard Pencek
Mark Pruzanski
Cathi Sciacca
David Shapiro
Ikuko Taoka
Original Assignee
Intercept Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57198868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41999(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd filed Critical Intercept Pharmaceuticals Inc
Publication of MA41999A publication Critical patent/MA41999A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA041999A 2015-04-27 2016-04-26 Compositions d'acide obéticholique et procédés d'utilisation MA41999A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153040P 2015-04-27 2015-04-27
US201662317933P 2016-04-04 2016-04-04

Publications (1)

Publication Number Publication Date
MA41999A true MA41999A (fr) 2018-03-07

Family

ID=57198868

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041999A MA41999A (fr) 2015-04-27 2016-04-26 Compositions d'acide obéticholique et procédés d'utilisation

Country Status (25)

Country Link
US (9) US10052337B2 (fr)
EP (3) EP4371616A3 (fr)
JP (2) JP6941057B2 (fr)
KR (1) KR20170140325A (fr)
CN (1) CN107531742A (fr)
AU (2) AU2016255045B2 (fr)
BR (1) BR112017023161A2 (fr)
CA (1) CA2983609C (fr)
CL (1) CL2017002727A1 (fr)
CO (1) CO2017011535A2 (fr)
CR (1) CR20170492A (fr)
EA (1) EA201792354A1 (fr)
EC (1) ECSP17078433A (fr)
IL (2) IL294575A (fr)
MA (1) MA41999A (fr)
MX (1) MX2017013805A (fr)
NI (1) NI201700128A (fr)
PE (1) PE20180690A1 (fr)
PH (1) PH12017501956A1 (fr)
SG (2) SG10202003110PA (fr)
SV (1) SV2017005555A (fr)
TN (1) TN2017000452A1 (fr)
TW (1) TWI723017B (fr)
WO (1) WO2016176208A1 (fr)
ZA (1) ZA201707981B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (fr) 2010-05-06 2011-11-10 Children's Hospital Medical Center Procédés et systèmes de conversion de cellules précurseurs en tissus intestinaux par différenciation dirigée
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
CA2963704A1 (fr) 2014-10-17 2016-04-21 Children's Hospital Medical Center Modele in vivo d'intestin grele humain faisant intervenir des cellules souches pluripotentes et ses procedes de fabrication et d'utilisation
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
EP3437645B1 (fr) * 2016-03-31 2021-09-22 Intercept Pharmaceuticals, Inc. Comprimé enrobé d'un film et présentant une stabilité chimique élevée de son principe actif
CA3020698A1 (fr) * 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methodes de traitement ou de prevention du carcinome hepatocellulaire
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
CN109640981A (zh) * 2016-06-29 2019-04-16 曼隆治疗公司 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途
SG10202104575WA (en) * 2016-11-04 2021-06-29 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
CN108072729A (zh) * 2016-11-18 2018-05-25 华北制药集团新药研究开发有限责任公司 一种测定奥贝胆酸片溶出度的方法
CA3045145A1 (fr) 2016-12-05 2018-06-14 Children's Hospital Medical Center Organoides du colon et leurs procedes de preparation et d'utilisation
CN108614038B (zh) * 2016-12-13 2022-05-17 亚宝药业集团股份有限公司 一种测定奥贝胆酸原料药有关物质的方法
CN106645497A (zh) * 2017-01-03 2017-05-10 山东省药学科学院 一种奥贝胆酸及其制剂中有关物质的检测方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
CA3070837A1 (fr) 2017-07-24 2019-01-31 Intercept Pharmaceuticals, Inc. Derives d'acide biliaire a marquage isotopique
WO2019074793A1 (fr) 2017-10-10 2019-04-18 Children's Hospital Medical Center Compositions de tissus oesophagiens et/ou d'organoïdes et leurs procédés de fabrication
WO2019106043A1 (fr) * 2017-11-29 2019-06-06 Hexal Ag Composition pharmaceutique comprenant de l'acide obéticholique
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
CN108572251B (zh) * 2018-05-31 2020-01-17 中国科学院昆明动物研究所 肝硬化早期小分子标志物及其应用
CA3106634A1 (fr) 2018-07-26 2020-01-30 Children's Hospital Medical Center Tissus hepato-bilio-pancreatiques et methodes permettant de les obtenir
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
CN112823012A (zh) 2018-09-12 2021-05-18 儿童医院医学中心 用于产生造血干细胞及其衍生物的类器官组合物
CA3117966A1 (fr) * 2018-11-08 2020-05-14 Intercept Pharmaceuticals, Inc. Methodes d'utilisation d'acide obeticholique
CN109432431B (zh) * 2018-12-14 2020-06-30 中国药科大学 一种含有sumo抑制剂的组合物及应用
CN109655571B (zh) * 2019-01-08 2021-07-13 丽珠集团新北江制药股份有限公司 一种奥贝胆酸的高效液相色谱分析方法
CN109620812B (zh) * 2019-01-16 2023-07-21 浙江华海药业股份有限公司 一种奥贝胆酸组合物的制备方法
WO2020160371A1 (fr) 2019-02-01 2020-08-06 The University Of Hong Kong Compositions d'organoïdes innervés et leurs procédés de fabrication
WO2020198383A1 (fr) * 2019-03-26 2020-10-01 Intercept Pharmaceuticals, Inc. Méthodes de diagnostic et de traitement de maladies du foie à l'aide d'acide obéticholique
WO2020198576A1 (fr) * 2019-03-28 2020-10-01 The Board Of Trustees Of The University Of Illinois Procédés de modulation de lymphocytes t régulateurs
CA3141807A1 (fr) 2019-05-31 2020-12-03 Children's Hospital Medical Center Procedes de production et de multiplication de cellules souches hematopoietiques
US12534709B2 (en) 2019-05-31 2026-01-27 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CN114502198A (zh) * 2019-09-30 2022-05-13 诺华股份有限公司 包括使用fxr激动剂的治疗
EP4116710A4 (fr) * 2020-03-06 2024-04-24 Mili Healthcare Trade DMCC, Limited Liability Company Application d'un groupe de marqueurs pour le diagnostic et la modification de traitement de la cholangite biliaire primitive, composition pharmaceutique, et forme posologique solide pour le traitement de la cholangite biliaire primitive
CN111518152B (zh) * 2020-04-23 2022-11-22 江西青峰药业有限公司 一种3α,7α-二羟基-6α-乙基-5β-胆烷-24-醛的制备方法及其应用
US20230201222A1 (en) * 2020-05-13 2023-06-29 Children's Hospital Medical Center Alleviation of liver injury by activating the signaling pathway mediated by farnesoid x receptor
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN111812264B (zh) * 2020-07-09 2021-06-15 苏州旭辉检测有限公司 一种去氧胆酸类化合物的生物样品分析方法
WO2022051321A1 (fr) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Combinaisons de doses fixes de chs-131 et d'un agoniste de fxr
WO2022076683A1 (fr) * 2020-10-07 2022-04-14 Intercept Pharmaceuticals, Inc. Méthodes de traitement d'une infection à coronavirus à l'aide d'acide obéticholique
CN113143950B (zh) * 2021-05-17 2023-04-18 河北医科大学第二医院 一种治疗肝病的药物组合物及其应用
WO2023147141A1 (fr) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Polythérapie
WO2023181077A1 (fr) * 2022-03-24 2023-09-28 Zenvision Pharma Llp Composition liquide stable comprenant de l'acide obéticholique ou des sels de celui-ci
US12343351B2 (en) 2022-03-25 2025-07-01 Rutgers, The State University Of New Jersey Pulmonary function treatment
KR20250006156A (ko) * 2022-04-21 2025-01-10 인터셉트 파마슈티컬즈, 인크. 파르네소이드 x 수용체 효능제의 용도
US20260183243A1 (en) * 2022-07-25 2026-07-02 Shilpa Medicare Limited Pharmaceutical compositions of nor-udca
WO2024043842A1 (fr) * 2022-08-22 2024-02-29 Pharmactive Ilac Sanayi Ve Ticaret A.S. Compositions pharmaceutiques comprenant de l'acide chénodésoxycholique (cdca) en tant que principe actif et d'autres excipients pertinents
WO2024104960A1 (fr) 2022-11-15 2024-05-23 Synthon B.V. Formulation stable comprenant de l'acide obéticholique

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
ZA876640B (en) * 1986-09-26 1988-03-08 Warner-Lambert Company Treated lipid regulator
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DK1392714T3 (da) * 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
CN100350977C (zh) 2001-06-14 2007-11-28 大塚制药株式会社 药物组合物
US6933380B2 (en) 2001-10-19 2005-08-23 Yung-Zip Chemical Ind. Co., Ltd. Excipients containing low residual solvent and method for producing the same
JP2006509722A (ja) * 2002-07-03 2006-03-23 エスペリオン セラピューティクス，インコーポレイテッド 脂質代謝異常を治療するためのパンテチン含有組成物
US20050101505A1 (en) * 2003-11-06 2005-05-12 Daniel Wood Liquid laundry detergent composition having improved color-care properties
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US8074906B2 (en) 2005-07-07 2011-12-13 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
JP2012520866A (ja) * 2009-03-17 2012-09-10 アプタリス・ファーマ・カナダ・インコーポレイテッド 高用量のウルソデオキシコール酸で非アルコール性脂肪性肝炎を治療する方法
CA2759109A1 (fr) 2009-04-24 2010-10-28 Iceutica Pty Ltd Une forme de dosage solide de ciprofloxacine ayant des particules de petites taille et des caracteristiques de manipulation de poudre ameliorees
BR112012026843A2 (pt) 2010-04-20 2016-07-12 Cipla Ltd composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
ES2822375T3 (es) * 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
KR20150127599A (ko) 2013-03-15 2015-11-17 모치다 세이야쿠 가부시키가이샤 비알코올성 지방간염을 치료하기 위한 조성물 및 방법
CN105377870B (zh) 2013-05-14 2018-04-03 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物
MX377523B (es) 2013-09-11 2025-03-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
CN105801653B (zh) 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso

Also Published As

Publication number Publication date
EP3971199A1 (fr) 2022-03-23
WO2016176208A1 (fr) 2016-11-03
TN2017000452A1 (en) 2019-04-12
PH12017501956A1 (en) 2018-03-26
AU2016255045B2 (en) 2020-04-16
US10052337B2 (en) 2018-08-21
SG10202003110PA (en) 2020-05-28
KR20170140325A (ko) 2017-12-20
EP4371616A3 (fr) 2024-08-28
AU2020205315A1 (en) 2020-08-06
US20220133745A1 (en) 2022-05-05
IL255269A (en) 2018-02-28
ECSP17078433A (es) 2018-02-28
EP3288958A4 (fr) 2018-09-26
EP4371616A2 (fr) 2024-05-22
JP2021183651A (ja) 2021-12-02
JP2018514534A (ja) 2018-06-07
PE20180690A1 (es) 2018-04-23
US20200054650A1 (en) 2020-02-20
US20200046735A1 (en) 2020-02-13
JP6941057B2 (ja) 2021-09-29
ZA201707981B (en) 2019-03-27
US20190255071A1 (en) 2019-08-22
SV2017005555A (es) 2019-01-18
CO2017011535A2 (es) 2018-01-31
US20190076446A1 (en) 2019-03-14
US10758549B2 (en) 2020-09-01
MX2017013805A (es) 2018-09-06
CA2983609A1 (fr) 2016-11-03
TWI723017B (zh) 2021-04-01
US20170035784A1 (en) 2017-02-09
EP3288958A1 (fr) 2018-03-07
SG11201708606VA (en) 2017-11-29
NI201700128A (es) 2018-04-11
AU2016255045A1 (en) 2017-11-09
US10646499B2 (en) 2020-05-12
CN107531742A (zh) 2018-01-02
US20200171053A1 (en) 2020-06-04
CA2983609C (fr) 2024-05-07
US20200046736A1 (en) 2020-02-13
US20260000682A1 (en) 2026-01-01
CL2017002727A1 (es) 2018-04-27
BR112017023161A2 (pt) 2018-07-24
CR20170492A (es) 2018-05-15
IL255269B (en) 2022-08-01
EA201792354A1 (ru) 2018-03-30
US10751349B2 (en) 2020-08-25
IL294575A (en) 2022-09-01
TW201703773A (zh) 2017-02-01

Similar Documents

Publication Publication Date Title
EP3704239A4 (fr) Compositions de casz et procédés d'utilisation
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
EP3352774A4 (fr) Compositions de flavonoïdes et procédés d'utilisation
EP3307762A4 (fr) Variants de cas9 rapporteurs et leurs procédés d'utilisation
EP3414321A4 (fr) Compositions améliorant vcn et procédés d'utilisation desdites compositions
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
EP3303634A4 (fr) Variants de cas9 et procédés d'utilisation associés
EP3313404A4 (fr) Compositions thérapeutiques, associations et procédés d'utilisation
EP3298168A4 (fr) Agents réducteurs stabilisés et leurs procédés d'utilisation
EP3341017A4 (fr) Compositions d'immunomodulation et leurs procédés d'utilisation
MA41558A (fr) Compositions d'allergènes mélangés et leurs procédés d'utilisation
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
EP2964235A4 (fr) Compositions antimicrobiennes-antibiofilm et leurs procédés d'utilisation
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3377615A4 (fr) Compositions d'induction d'haploïdes et procédés d'utilisation associés
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
EP3386927A4 (fr) Compositions polymères et procédés d'utilisation
EP2996694A4 (fr) Compositions de cénicriviroc et leurs procédés de fabrication et d'utilisation
EP3478277A4 (fr) Compositions anti-acné et procédés d'utilisation
EP3490569A4 (fr) Compositions topiques et ses procédés d'utilisation
MA46044A (fr) Compositions de nettoyage comprenant un acide aminé et leurs procédés d'utilisation
EP3390676A4 (fr) Adjuvants de lixiviation et leurs procédés d'utilisation
EP3113613A4 (fr) Compositions d'ester de choline de l'acide lipoïque et procédés d'utilisation correspondants